Analysis Interface
In the analysis interface, you can clearly see the specific target of each type of immunotherapy. The target
with a red background indicates that the target has an approved immunotherapy, and the yellow background
indicates that the drug for the target is currently in the clinical research stage. If you want to know the
current research status of a specific target, which drugs are approved, and what diseases are these drugs
designed for, you can learn more by clicking on the specific target.
If you want to predict the binding affinity of both MHC (including, MHC I and MHC II) and peptide, and TCR and peptide, you can choose different methods to predict the relevant results by selecting the option of MHC & peptide or TCR & peptide in the "Predict you want" box below.
If you want to predict the binding affinity of both MHC (including, MHC I and MHC II) and peptide, and TCR and peptide, you can choose different methods to predict the relevant results by selecting the option of MHC & peptide or TCR & peptide in the "Predict you want" box below.
Predict you want
Adoptive cell therapies
CIK
CTL
DC-CIK
NK
NKT
TIL
5T4
AFP
BCMA
CD123
CD19/CD22
CD30
CD33
CD38
CD40
CD5
CD56
CEA
EBV-related antigens
GD2
GPC3
GP100
HBV
HER2
HPV-related antigens
MAGE antigens
MAGE-A4
Mesothelin
MUC-1
NY-ESO-1
PSCA
PSMA
LMP2
WT1
Claudin 18.2
Claudin 6
KK-LC-1
CLL1
PD-L1
HA-1
NKG2D
Cytomegalo virus
Tumor-associated antigens
Tumor-specific antigens
Neoepitope
LAGE-1a
TGF-β
GPRC5D
Gene
Target
Drug
Disease
MHC
Target
peptide
TCR
CDR3.alpha/CDR3.beta
Drug
Disease
This target has not yet been studied in clinical trials, and there is no clear evidence of target
interaction. We will update the information in time if relevant data appears in the follow-up. If you
have evidence to support this target relationship, you can also provide it to us on the Submission page,
and we greatly appreciate your submission.